Could the Road to an AKS Violation Be Paved with Good Intentions? Pfizer Asks SCOTUS
FDA Law Blog
NOVEMBER 6, 2022
Pfizer challenged the OIG’s interpretation as contrary to law in a lawsuit brought in the Southern District of New York (SDNY). The Second Circuit’s Interpretation of the AKS and its Mens Rea Element. Pfizer appealed to the Second Circuit, which again ruled against Pfizer.
83 
Let's personalize your content